PT  - JOURNAL ARTICLE
AU  - Bloom, Joshua S.
AU  - Sathe, Laila
AU  - Munugala, Chetan
AU  - Jones, Eric M.
AU  - Gasperini, Molly
AU  - Lubock, Nathan B.
AU  - Yarza, Fauna
AU  - Thompson, Erin M.
AU  - Kovary, Kyle M.
AU  - Park, Jimin
AU  - Marquette, Dawn
AU  - Kay, Stephania
AU  - Lucas, Mark
AU  - Love, TreQuan
AU  - Booeshaghi, A. Sina
AU  - Brandenberg, Oliver F.
AU  - Guo, Longhua
AU  - Boocock, James
AU  - Hochman, Myles
AU  - Simpkins, Scott W.
AU  - Lin, Isabella
AU  - LaPierre, Nathan
AU  - Hong, Duke
AU  - Zhang, Yi
AU  - Oland, Gabriel
AU  - Choe, Bianca Judy
AU  - Chandrasekaran, Sukantha
AU  - Hilt, Evann E.
AU  - Butte, Manish J.
AU  - Damoiseaux, Robert
AU  - Kravit, Clifford
AU  - Cooper, Aaron R.
AU  - Yin, Yi
AU  - Pachter, Lior
AU  - Garner, Omai B.
AU  - Flint, Jonathan
AU  - Eskin, Eleazar
AU  - Luo, Chongyuan
AU  - Kosuri, Sriram
AU  - Kruglyak, Leonid
AU  - Arboleda, Valerie A.
TI  - Swab-Seq: A high-throughput platform for massively scaled up SARS-CoV-2 testing
AID  - 10.1101/2020.08.04.20167874
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.08.04.20167874
4099  - http://medrxiv.org/content/early/2021/03/09/2020.08.04.20167874.short
4100  - http://medrxiv.org/content/early/2021/03/09/2020.08.04.20167874.full
AB  - The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is due to the high rates of transmission by individuals who are asymptomatic at the time of transmission1, 2. Frequent, widespread testing of the asymptomatic population for SARS-CoV-2 is essential to suppress viral transmission. Despite increases in testing capacity, multiple challenges remain in deploying traditional reverse transcription and quantitative PCR (RT-qPCR) tests at the scale required for population screening of asymptomatic individuals. We have developed SwabSeq, a high-throughput testing platform for SARS-CoV-2 that uses next-generation sequencing as a readout. SwabSeq employs sample-specific molecular barcodes to enable thousands of samples to be combined and simultaneously analyzed for the presence or absence of SARS-CoV-2 in a single run. Importantly, SwabSeq incorporates an in vitro RNA standard that mimics the viral amplicon, but can be distinguished by sequencing. This standard allows for end-point rather than quantitative PCR, improves quantitation, reduces requirements for automation and sample-to-sample normalization, enables purification-free detection, and gives better ability to call true negatives. After setting up SwabSeq in a high-complexity CLIA laboratory, we performed more than 80,000 tests for COVID-19 in less than two months, confirming in a real world setting that SwabSeq inexpensively delivers highly sensitive and specific results at scale, with a turn-around of less than 24 hours. Our clinical laboratory uses SwabSeq to test both nasal and saliva samples without RNA extraction, while maintaining analytical sensitivity comparable to or better than traditional RT-qPCR tests. Moving forward, SwabSeq can rapidly scale up testing to mitigate devastating spread of novel pathogens.Competing Interest StatementE.M.J, M.G., N.B.L., S.W.S., F.Y., E.M.T., K.M.K., and J.P., and S.K. are employed by and hold equity, J.S.B. consults for and holds equity, and A.R.C holds equity in Octant Inc. which initially developed SwabSeq, and has filed for patents for some of the work here, though they have been made available under the Open Covid License: https://www.notion.so/Octant-COVID-License-816b04b442674433a2a58bff2d8288df.Funding StatementWe thank the UCLA David Geffen School of Medicine's Dean's Office for their support, the Fast Grants, Inc for funding of this work. A generous donation was provided by Jane Semel. We also thank the Held Foundation and the Carol Moss Foundation for their support of this project. This work was supported by funding from the Howard Hughes Medical Institute (to LK) and DP5OD024579 (to VA). IL is supported by T32GM008042.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were obtained with UCLA IRB approval under studies IRB#20-000527 and IRB#20-001157.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSoftware and data are available at the shared github links. The core technology has been made available under the Open Covid Pledge, and software and data under the MIT license (UCLA) and Apache 2.0 license (Octant). https://github.com/joshsbloom/swabseq https://github.com/joshsbloom/swabseqr https://github.com/octantbio/SwabSeq